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CORRESPONDENCE
Letters to the Editor
Detection of Pathologic or Physiologic
Left Ventricular Remodeling in Athletes
In a recent issue of the Journal, Whalley et al. (1) analyzed
echocardiographic left ventricular (LV) modifications due to train-
ing in a small cohort of endurance male athletes as compared to an
untrained control group. They found that body fat-free mass
(FFM)—as measured by dual-photon X-ray absorptiometry—was
the only independent predictor of both left ventricular mass
(LVM) and diastolic diameter (LVDD) in athletes, suggesting
that LV remodeling could reflect a normal physiologic response to
training-induced increased FFM.
Interestingly, although FFM is technically difficult to assess in
current clinical practice, Whalley et al. (1) also noted that, by
indexing LVM and LVDD to height2.7, there was no longer any
difference between athletes and controls, suggesting that this
simple approach might be relevant to eliminate pathologic LV
hypertrophy in endurance athletes.
We recently reported echocardiographic characteristics of a
large cohort of 286 professional cyclists (2), a sport that combines
endurance and resistance training and where performance-
enhancing drugs are frequently used (3). In these very highly
trained athletes, LV remodeling was markedly more important
than in the study by Whalley et al. (1) (60.1  3.9 vs. 55.6  0.62
mm for LVDD and 141  21 vs. 94  3 g/m2 for LVM/body
surface area [BSA], respectively). As in the Whalley study,
differences with an untrained control group (n  52) persisted
despite indexation to BSA. However, as opposed to the Whalley
et al. (1) study, indexation to height2.7 was not efficient to abolish
differences between athletes and controls, neither for LVD/
height2.7 (12.6  1.1 vs. 10.6  1.2 mm/m2.7, respectively, p 
0.0001), nor for LVM/height2.7 (55.7  8.7 vs. 29.5  4.8
mm/m2.7, respectively, p  0.0001; E. Abergel, unpublished data,
2004).
Thus, the conclusions by Whalley et al. (1) might not apply to
nonendurance and/or very highly trained athletes. These conflict-
ing results might also suggest that LV remodeling partially reflects
a pharmacological intervention and that height2,7 indexation could
be a simple screening test to suspect drug abuse in high-level
endurance athletes.
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REPLY
We thank Drs. Abergel and Hagege for their interest in our
research (1). They point to their own work (2) that indicates that
professional cyclists may have more left ventricular (LV) hypertro-
phy and dilation (2) than the weight-bearing endurance athletes
(runners) that we investigated. We chose not to include cyclists in
our study because of the altered loading conditions they endure
while training and the potential for the use of performance-
enhancing drugs, as mentioned by Abergel et al. (2).
We do not advocate height or height2.7 to be the perfect
indexation measure to assess ventricular size, but in the absence of
fat-free mass it does appear to be a reasonable surrogate in our
small group of athletes (1). However, as mentioned in our report,
indexing measurements to height will not take into account
longitudinal changes that occur with training, especially when
training is associated with altered fat-free mass.
With reference to the data presented by Abergel et al. (2), in the
absence of fat-free mass measurements, it would be difficult to
ascertain whether the increased LV size is physiologic or patho-
logic; moreover, it may be the case that the relationship between
fat-free mass and LV size observed in runners does not extend to
other trained athletes, nor in fact all runners. We believe our study
(1) was the first to demonstrate this relationship in athletes and, as
we concluded in our report, this requires further confirmation in
other groups of athletes.
*Gillian A. Whalley, MHSc, DMU
Robert N. Doughty, MD, FRACP
James C. Baldi, PhD
*Department of Medicine
University of Auckland
Private Bag 92 019
Auckland
New Zealand
E-mail: g.whalley@auckland.ac.nz
doi:10.1016/j.jacc.2005.02.048
REFERENCES
1. Whalley GA, Doughty RN, Gamble GD, et al. Association of
fat-free mass and training status with left ventricular size and
mass in endurance-trained athletes. J Am Coll Cardiol 2004;44:
892–6.
2. Abergel E, Chatellier G, Hagege AA, et al. Serial left ventricular
adaptations in world-class professional cyclists: implications for disease
screening and follow-up. J Am Coll Cardiol 2004;44:144–9.
Journal of the American College of Cardiology Vol. 45, No. 10, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
Published by Elsevier Inc.
